Form 4: Pliant Therapeutics CEO Sells Shares for Tax Obligations

Pliant Therapeutics' President and CEO, Bernard Coulie, sold 89,375 shares of common stock to cover tax liabilities from vested restricted stock units.

Summary

• Bernard Coulie, President and CEO of Pliant Therapeutics, Inc. (PLRX), reported a sale of common stock.
• The transaction involved the disposition of 89,375 shares of Common Stock.
• The sale occurred on January 20, 2026, at a weighted average price of $1.28 per share.
• This was a non-discretionary sale executed under a Rule 10b5-1 plan, intended to satisfy withholding tax liability in connection with the vesting of previously granted restricted stock units.
• Following the transaction, Bernard Coulie directly owns 505,601 shares of Common Stock.
• Additionally, 409,317 shares are indirectly owned through The Coulie/Leyman Family Trust, where Bernard Coulie and his spouse serve as trustees.
• The direct ownership includes 1,959 shares of Common Stock acquired by Bernard Coulie pursuant to an Employee Stock Purchase Program.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, non-discretionary sale for tax purposes related to equity compensation, which is a common occurrence for executives and does not inherently signal positive or negative sentiment about the company's future prospects.

Positives

• The sale was non-discretionary and pre-planned under Rule 10b5-1, indicating a structured approach to managing equity compensation and tax obligations rather than a discretionary sale based on market outlook.
• The transaction is related to the vesting of previously granted restricted stock units, which implies successful achievement of performance milestones or tenure.
• Bernard Coulie acquired 1,959 shares through an Employee Stock Purchase Program, indicating continued participation in company equity programs.

Negatives

• A significant number of shares (89,375) were sold, which reduces the direct beneficial ownership of the President and CEO.
• The sale price of $1.28 per share (weighted average) might be considered low depending on the company's historical stock performance and future prospects, though the primary driver was tax obligations.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale represents a reduction in the CEO's direct beneficial ownership, but as a routine tax-related transaction under a pre-arranged plan, it is generally not interpreted as a negative signal regarding the company's future.
• Employees: The sale was part of a group of employees selling shares for tax purposes, indicating a broader vesting event for equity compensation within the company.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by the CEO to cover tax obligations arising from vested restricted stock units. This type of transaction, executed under a Rule 10b5-1 plan, is a common occurrence for executives and typically does not reflect a change in management's outlook on the company's fundamentals or future prospects. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

PLRX, Pliant Therapeutics, Bernard Coulie, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Restricted Stock Units, Tax Withholding, CEO